EMA Authorised: Ajovy (fremanezumab) — Teva GmbH

View source ↗

Summary

The European Medicines Agency authorised Ajovy (fremanezumab) by Teva GmbH for migraine disorders, marking EU marketing authorization for this therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Ajovy (fremanezumab)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: Teva GmbH. Decision date: 27/03/2025